Ovarian Cancer
📧 Sign up to get email alerts when something new happens for Ovarian Cancer.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-04-24EMA Authorised: Caelyx pegylated liposomal (doxorubicin hydrochloride) — Baxter Holding B.V.
EMA authorised Caelyx pegylated liposomal doxorubicin hydrochloride for Kaposi's sarcoma, multiple myeloma, ovarian cancer, and breast cance…
-
EMA approval · 2026-04-16EMA Authorised: Zolsketil pegylated liposomal (doxorubicin hydrochloride, liposomal) — Accord Healthcare S.L.U.
The EMA authorised Zolsketil pegylated liposomal doxorubicin for ovarian cancer, Kaposi sarcoma, and multiple myeloma. The Marketing Authori…
-
EMA approval · 2026-03-25EMA Authorised: Trabectedin Accord (trabectedin) — Accord Healthcare S.L.U.
The European Medicines Agency authorised Accord Healthcare's trabectedin (Trabectedin Accord) for use in sarcoma and ovarian cancer.
-
EMA approval · 2026-03-19EMA Authorised: Lynparza (olaparib) — AstraZeneca AB
The EMA authorised Lynparza (olaparib) for multiple cancers in the European Union. Indications include ovarian cancer, breast cancer, pancre…
-
EMA approval · 2026-02-06EMA Authorised: Alymsys (bevacizumab) — Mabxience Research SL
The EMA authorised Alymsys, a bevacizumab biosimilar from Mabxience Research SL. It is approved for multiple cancer indications including co…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-02-05EMA Authorised: Avzivi (bevacizumab) — FGK Representative Service GmbH
EMA authorised Avzivi (bevacizumab) for multiple indications including colorectal cancer, non-small cell lung cancer, renal cell carcinoma, …
-
EMA approval · 2026-01-28EMA Authorised: Abevmy (bevacizumab) — Biosimilar Collaborations Ireland Limited
EMA authorised Abevmy (bevacizumab) as a biosimilar. It is approved for several cancer indications including colorectal, breast, ovarian, fa…
-
EMA approval · 2026-01-28EMA Authorised: Oyavas (bevacizumab) — STADA Arzneimittel AG
EMA authorised Oyavas, a bevacizumab biosimilar by STADA, for multiple indications including colorectal, breast, ovarian, fallopian tube, pe…
-
EMA approval · 2026-01-28EMA Authorised: Vegzelma (bevacizumab) — Celltrion Healthcare Hungary Kft.
EMA authorised Vegzelma, a bevacizumab biosimilar from Celltrion Healthcare Hungary Kft., for multiple cancers including colorectal, breast,…
-
EMA approval · 2026-01-28EMA Authorised: Aybintio (bevacizumab) — Samsung Bioepis NL B.V.
The EMA authorised Aybintio, a bevacizumab biosimilar from Samsung Bioepis NL B.V., for multiple cancer indications including colorectal, br…
-
EMA approval · 2026-01-27EMA Authorised: Mvasi (bevacizumab) — Amgen Technology (Ireland) UC
EMA authorised Mvasi (bevacizumab) from Amgen as a biosimilar to bevacizumab for multiple cancer indications including renal cell carcinoma,…
-
EMA approval · 2026-01-27EMA Authorised: Avastin (bevacizumab) — Roche Registration GmbH
The EMA authorised Avastin (bevacizumab) under Roche Registration GmbH for multiple cancer indications. The listed diseases include non-smal…
-
EMA approval · 2026-01-23EMA Authorised: Elahere (mirvetuximab soravtansine) — AbbVie Deutschland GmbH & Co. KG
The European Medicines Agency authorised Elahere (mirvetuximab soravtansine) for ovarian cancer, fallopian tube cancer and peritoneal cancer…
-
EMA approval · 2026-01-20EMA Authorised: Hycamtin (topotecan) — Sandoz Pharmaceuticals d.d.
EMA authorised Hycamtin (topotecan) by Sandoz Pharmaceuticals d.d. for the treatment of ovarian cancer, cervical cancer, and small cell lung…
-
FDA approval · 2024-12-19FDA Approved: CYCLOPHOSPHAMIDE — Original Application (BluePoint Laboratories)
FDA approved BluePoint Laboratories' original ANDA for cyclophosphamide, establishing a generic version of the chemotherapy agent.
-
FDA approval · 2024-10-29FDA Approved: CYCLOPHOSPHAMIDE — Original Application (Nexus Pharmaceuticals, LLC)
FDA approved Nexus Pharmaceuticals, LLC to market a generic cyclophosphamide product under Original Application ANDA216783.
-
FDA approval · 2024-05-10FDA Approved: CISPLATIN — Original Application (Apotex Corp.)
FDA approved the original application for cisplatin from Apotex Corp., enabling the generic version to be marketed in the United States.
-
FDA approval · 2024-03-22FDA Approved: ELAHERE — Supplemental Application (ImmunoGen, Inc.)
FDA approves a supplemental application for ELAHERE (mirvetuximab soravtansine) from ImmunoGen, Inc. The approval updates the labeling to re…
-
FDA approval · 2023-09-19FDA Approved: DOCETAXEL — Supplemental Application (Amneal Pharmaceuticals LLC)
The FDA approved Amneal's supplemental application to manufacture and market a generic docetaxel, enabling its supply for cancer treatment i…
-
FDA approval · 2023-09-15FDA Approved: DOCETAXEL — Supplemental Application (Gland Pharma Limited)
FDA approved a supplemental application for docetaxel from Gland Pharma Limited under an ANDA for the generic product.
-
FDA approval · 2023-08-18FDA Approved: IVRA — Original Application (Apotex Corp)
FDA approved Apotex Corp's original application for IVRA, an intravenous melphalan hydrochloride formulation.
-
FDA approval · 2023-06-16FDA Approved: CARBOPLATIN — Supplemental Application (Apotex Corp.)
FDA approved Apotex Corp.'s supplemental application for generic carboplatin. This action permits Apotex to market a generic carboplatin for…
-
FDA approval · 2023-05-31FDA Approved: LYNPARZA — Supplemental Application (AstraZeneca Pharmaceuticals LP)
The FDA approved a supplemental application for LYNPARZA (olaparib) from AstraZeneca Pharmaceuticals LP, resulting in changes to the product…
-
FDA approval · 2023-04-26FDA Approved: ZEJULA — Original Application (GlaxoSmithKline LLC)
FDA approved ZEJULA (niraparib) in an original application submitted by GlaxoSmithKline LLC.
-
FDA approval · 2023-03-07FDA Approved: GEMCITABINE — Original Application (Hikma Pharmaceuticals USA Inc.)
FDA approved Hikma Pharmaceuticals USA Inc.'s generic gemcitabine under an Original Application (ANDA). This marks the approval of a generic…